ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 881

Microrna-155 Regulates Chemokines and Chemokine Receptors in Rheumatoid Arthritis Monocyte

Aziza Elmesmari1, Derek S. Gilchrist1, Alasdair R. Fraser1, Diane Vaughan1, Ross McQueenie2, Gerard J. Graham1, James Brewer3, Iain B. McInnes1 and Mariola Kurowska-Stolarska1, 1Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 2Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3Immunology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: chemokines, monocytes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Rheumatoid arthritis (RA) is characterized by synovial tissue inflammation leading to joint destruction. Monocytes/macrophages are major effector cells in RA synovitis, principally by releasing TNF-α, IL-6 and other inflammatory cytokines and chemokines. MicroRNAs are a recently discovered class of post-transcriptional regulators –in particular miR-155 is upregulated in RA synovial macrophages where it regulates cytokine expression. We hypothesized that miR-155 regulates migration of monocytes by modulating the chemokine and chemokine receptor system.

Methods: Peripheral blood (PB) was obtained from healthy controls and RA patients who met the 2010 ACR/EULAR diagnostic criteria. Purified CD14+ PB monocytes obtained by magnetic bead isolation were transfected with miR-155 mimic or scrambled mimic using an N-TER nanoparticle system. Taqman Low Density Array and Luminex multiplex assay was used to evaluate chemokine receptor gene expression and chemokine production, respectively. Absolute copy numbers of miR-155 transcripts in PB and SF monocytes of RA and healthy controls were assessed by QPCR. The role of mir155 was investigated further using bone marrow monocytes (BMM) from miR-155-/-and WT mice.

Results: RA PB and SF macrophages showed higher copy number of miR-155 compared with healthy controls. Overexpression of miR-155 induced the production of chemokines CCL4, CCL5, CCL8 and CCL22 in RA monocytes and CCL3 in both RA and healthy controls. However, overexpression of miR-155 in healthy control and RA monocytes did not affect the production of CCL2, CCL7, CCL21, CXCL5, CXCL8, CXCL7, CXCL10 and CX3CL1. Analysis of chemokine receptors in BMM of miR-155-/- and WT mice revealed significantly higher levels of CCR1, CCR2, CCR5 and CXCR4 in miR-155 deficient cells suggesting that miR-155 can act as a negative regulator of these receptors in homeostatic state. TLR-4 ligand significantly suppressed expression of these receptors in both WT and miR-155-/-cells. Analysis of 3’UTRs of chemokine and chemokine receptor (TargetScan) suggests that miR-155 likely interferes with signaling pathways implicated in chemokine and chemokine receptor system expression.

Conclusion: Deregulation of miR-155 in RA monocytes can contribute to the production of pro-inflammatory chemokines by these cells and to their accumulation at sites of inflammation.


Disclosure:

A. Elmesmari,
None;

D. S. Gilchrist,
None;

A. R. Fraser,
None;

D. Vaughan,
None;

R. McQueenie,
None;

G. J. Graham,
None;

J. Brewer,
None;

I. B. McInnes,
None;

M. Kurowska-Stolarska,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microrna-155-regulates-chemokines-and-chemokine-receptors-in-rheumatoid-arthritis-monocyte/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology